A report released by Transparency Market Research (TMR) pegs the value of the global liver diseases therapeutics market at US$6.5 bn in 2011. The market, according to the report, is likely to reach US$10.9 bn by the end of 2018. If the figures hold true, the global liver diseases therapeutics market will exhibit a CAGR of 8.60% between 2012 and 2018. The report further states that among the entire class of drugs covered in the report, the segment of antiviral drugs is anticipated to lead the market during the forecast period between 2013 and 2018, particularly in terms of revenue. The anti-viral drugs segment will therefore hold 32.7% of the overall market, while the vaccines segment will account for 19.1% of the global liver diseases therapeutics market.The 112-page report is titled “Liver Diseases Therapeutics Market – Global Industry Analysis, Size, Share, Trends And Forecast 2012 – 2018” and is available on TMR’s official website for sale.
Widespread prevalence of liver diseases and disorders, increasing geriatric population, and prevalence of unmet medical needs in the case of liver cancer are the primary factors augmenting the demand for effective liver disease therapeutics. Additionally, emerging economies are focusing on fuel vaccination drives to eradicate chronic ailments, which will also give a boost to the global market for liver disease therapeutics. Compiled with the intent of providing a comprehensive snapshot of the market, the report identifies several potential opportunities that may fuel the market’s growth in the future. The emerging markets in Eastern Europe, Latin America, and Asia Pacific, for instance, will provide lucrative prospects for the liver diseases therapeutics market, as these regions report high incidence of liver diseases. The high number of potentially highly effective and strong liver disease drugs in the pipeline presents promising opportunities for the overall healthcare industry.
Despite exhibiting a positive growth potential, the market, according to a lead TMR analyst, “Will face inhibitions on its growth due to stringent FDA regulations. The risk of side effects from liver diseases drugs and the availability of generic substitutes will also negatively impact the global market for liver disease therapeutics to an extent.”Apart from these restraints, the impending patent expiry of blockbuster drugs may also have an adverse impact on the overall market.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=799
For the purpose of the study, the report segments the global liver diseases therapeutics market into non-alcoholic fatty liver disease, autoimmune liver disease, viral/hepatitis liver disorder, hepatocellular carcinoma, and alcohol induced liver disease in terms of liver disease and therapy options. Based on drug class, the global liver diseases therapeutics market is segmented into immunosuppressants, antiviral drugs, targeted therapy drugs, immunoglobulins, chemotherapy drugs, vaccines, and corticosteroids. In terms of region, the global market is segmented into Asia Pacific, Europe, North America, and Rest of the World (RoW).To study the vendor landscape of the market, the report also profiles leading companies such as Pfizer, Novartis, Abbot Laboratories, Gilead Science Inc., Bristol-Myers Squibb, Astellas Pharma Inc., Merck & Co., and Roche.
The report classifies liver diseases and therapy options as follows:
- Alcohol induced liver disease
- Autoimmune liver disorder
- Hepatocellular carcinoma
- Non-alcoholic fatty liver disease
- Viral/hepatitis liver disorder
The report also studies the liver diseases therapeutics market based on drug class, as follows:
- Chemotherapy drugs
- Targeted therapy drugs
- Anti-viral drugs
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453